Q1 2023 Adaptive Biotechnologies Corporation Earnings Call
Speaker 1: Oh.
Speaker 2: Good day and thank you for standing by.
Speaker 2: Welcome to the adaptive biotechnology first quarter, twenty, twenty three conference call.
Speaker 2: At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automatic message advising your hand is right.
Speaker 2: To withdraw your questions, please press star 1-1 again. I would now like to hand the conference over to one of your speakers for today, Karina Cassadilla, Head of Investor Relations. Please play.
Speaker 3: Thank you, Brittany, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnology's first quarter of the 2023 Earnings Conference TH acknowledgeful and merciful.
Speaker 3: Earlier today, we should have press release reporting adaptive financial results for the first quarter of 2023. The press release is available at www.adaptifyotech.com. We are conducting a live webcast of this call and will be referenced into a slide presentation that has been posted to the Investors section in our corporate website.
Speaker 3: During the call, management will make projections another forward-looking statement within the meaning of federal security laws regarding future events and the future financial performance of the company. These statements reflect management current perspective of the business of today. Actual results may differ materially from today's forward-looking statement.
Speaker 3: depending on a number of factors which are set forth in our public filings with the SEC and listed in this presentation.
Speaker 3: In addition, non- GAAP financial measures will be discussed during the call, and every conciliation from non-gap to gap metrics can be found in our earnings release.
Speaker 3: Joining the call today are Chad Robbins, our CEO and co-founder, and Tycho Peterson, our chief financial officer. Hey, Chad, glad you're here.
Speaker 3: In addition, Harlan Robbins, adaptive chief scientific officer and co-founder, needs ensued head of MRG business and Shannon Senau, head of in-mune medicine business, will be also available for Q&A. With that, I'll turn the call over to Chad Robbins. Chad.
Speaker 4: Thanks, Karina. Good afternoon, everybody, and thank you for joining us on our first quarter of 2023 earnings call.
Speaker 4: First, I want to thank all our adaptive employees for their continued dedication and execution.
Speaker 4: This courters results represent a solid start to the year, laying the foundation for us to deliver on our 2023 annual goals.
Speaker 4: As shown on slide three, revenue for the quarter was 37.6 million, which reflects a 26% reduction in genetic amortization offset by strong recurring revenue growth from both our immune medicine and MRD businesses.
Speaker 4: We continue to streamline our organization and improve operating efficiencies.
Speaker 4: We recently announced the consolidation of the present and chief operating officer roles under Julie Rubenstein to better align operations with our path to profitability.
Speaker 4: Our research and development efforts and drug discovery continue to progress.
Speaker 4: Both programs in Cancer, South therapy with Genentech are advancing and are on track to achieve the respective goals set for this year. And our drug discovery team is making great progress towards novel targets in auto-immunity.
Speaker 4: Let's take a closer look at our MRD business on slide 4.
Speaker 4: Our MRD business is firing on all cylinders.
Speaker 4: MRD revenue growth for the quarter had strong growth of 20% versus prior year.
Speaker 4: Clonalcy Test Volume Group 57% with double digit volume growth in all marketed indications.
Speaker 4: Multimiloma continues to be the biggest growth driver and largest contributor.
Speaker 4: DLBCL launch is progressing well and now represents 3% of KelownaSeq orders.
Speaker 4: Ordering healthcare providers and ordering accounts experience significant growth of 58% and 56% versus prior year respectively.
Speaker 4: Blood-based testing, a key component of our growth strategy, increased in all indications include 30% versus prior quarter.
Speaker 4: Now, approximately 35% of all MRD tests are in blood compared to 31% last quarter.
Speaker 4: This growth in blood testing is mainly driven from our Salesforce strategy to penetrate community accounts.
Speaker 4: Community Day counts continue to grow quarter over quarter and now contribute about 18% of clemency volume versus 15% in the fourth quarter of last year.
Speaker 4: In addition, MRD Pharma, a core component of our MRD business grew 23% excluding regulatory milestones.
Speaker 4: We continue to grow our MRD partnerships.
Speaker 4: This quarter we entered into a new translational Pamphor Folio partnership with the Cata for the use of MRD as a clinical endpoint.
Speaker 4: Not only do we have a healthy sequencing revenue stream from these partnerships, but we also now have $400 million in future eligible milestones based on additional drug drug approvals from ongoing and future studies.
Speaker 4: Zuing into Closet Test Volume on Slide 5. As you can see from the chart, we continue to set Record High Volume's quarter over quarter.
Speaker 4: This quarter volume goofed 15% sequentially to over 12,000 test delivered.
Speaker 4: In the United States, our market of focus tests the liver grew 16% from last quarter.
Speaker 4: Our strategy to drive clonal-seat volume is working and we continue to drive ASP expansion with new pairs and improved collections.
Speaker 4: Of note, this quarter a new Cloniseek PLA code was approved, which allows us to uniquely identify Cloniseek in our claim submissions.
Speaker 4: As noted on slide 6, we are on track to achieve key milestones in 2023 for MRD.
Speaker 4: Our epic integration is on schedule as we look to bring pilot sites live next quarter with additional integration sites to follow.
Speaker 4: We also continue to expect meaningful data readouts in GLVCR in multiple my Loma in blood and therapy discontinuation.
Speaker 4: The setup for MRD is strong and we are confident that we will achieve over 50% that Planoshe test volume growth this year versus 2022.
Speaker 4: Switching to our immune medicine business on slide 7.
Speaker 4: We generated more than 16 million in revenue this quarter from two distinct areas, farmer services and drug discovery.
Speaker 4: Farmers Services generates revenue from multiple sources as we provide valuable and unresceptor data to our Viall farmer customers, accelerating their therapeutic programs.
Speaker 4: We have a healthy portfolio with more than 120 active studies that is set up to deliver sustainable growth of 20 to 30 percent tager over the next three to five years. Revenue from drug discovery this year reflects an expected deceleration due to the reduced amortization source of three hundred percent in a family distribution which occurs in providing
Speaker 4: of the genetic upfront payment.
Speaker 4: As you can see from the slide, there are multiple sources of revenue from farmer services that will contribute to growth. In addition, as we advance our drug discovery efforts, new revenue streams will drive future value.
Speaker 4: Our drug discovery programs in cancer and autoimmune disorders are on track to achieve the milestones shown on slide 8.
Speaker 4: We are making progress on our two cancer cell therapy programs with Genentech.
Speaker 4: For the first shared TCR candidate, we expect the first IND acceptance this year and continue to support Genentech to the clinic.
Speaker 4: For the personalized program, we are building the regulated infrastructure in our dedicated lab and are executing to optimize our process for clinical readiness.
Speaker 4: In our internal autoimmune programs, we are advancing our R&D efforts to identify and validate novel targets.
Speaker 4: We also are expanding our therapeutic TCR and antibody platforms with the goal of developing therapeutic assets to be able to drug these targets.
Speaker 4: We look forward to providing you with more updates as we progress. I'll now pass it over to Tyco. Next, Beth. Turning to our financial results. Starting with slide 9.
Speaker 4: Total revenue in the first quarter was 37.6 million, with 57% from MRD and 43% from immune medicine, representing a 3% decrease from the same period last year, which is primarily attributable to the expected stepdown in genetic amortization and a $3 million MRD regulatory milestone comp.
Speaker 4: Emergy revenue grew to 21.4 million, up 20% from a year ago, with strong growth from both clinical, testing, and formal partnerships.
Speaker 4: Total state test volume, including international, increased 57% to 12,079 tests delivered from 7,698 tests in the same period last year. Immunic medicine revenue was 16.2 million, down 22% from a year ago, given predominantly by genetic amortization. Moving down the P&L, total operating expenses.
Speaker 4: including cost of revenue for $94.8 million, representing a 7% decrease from a 101.7 million in the same period last year.
Speaker 4: Notably, R&D, sales and marketing, and G&A all declined Euro be here.
Speaker 4: The cost of revenue was 18.7 million, driven by higher usage of our production lab to process revenue samples, as well as a transitory increase in overhead due to the ongoing lab consolidation into our headquarters in Seattle.
Speaker 4: Finally, interest expense from a royalty financing agreement with Orman Ed was 3.5 million, which was almost entirely offset by interest income. Net loss for the quarter was 57.7 million compared to 62.8 million last year.
Speaker 4: We ended the quarter with approximately 441 million cash, equivalent and marketable securities.
Speaker 4: Turning to our outlook on slide 10, we are reiterating full-year revenue guidance of $205 to $215 million. At the midpoint, we expect the contribution from our businesses to be approximately 55% from MRD and 45% from immune medicine, and we expect revenue to be back halfway.
Speaker 4: Within our MRD business, we expect over 50% growth in clonal sheet cast volume and MRD regulatory milestones in the mid to high single digit millions.
Speaker 4: As we drive operating efficiencies, we are also reiterating our full year op-X targets, including cost of revenue, to be below 2022 op-X of $385.5 million. Cash preservation remains a priority, and we expect our burn for the remainder of 2023 to average around $40 million per quarter, which is unchanged from guidance at the beginning of the year.
Speaker 4: Of note, the Q1 cash program is higher due to usual bonus payouts and marks.
Speaker 4: To what financial results were solid and align with our expectations and we are on track to deliver full-year guidance.
Speaker 4: Importantly, we have a strong cast position to fuel growth and execute on our long-term goals. We were made committed to driving additional operating leverage and achieving positive EBITDA in 2025 and cast break even in 2026. I'll now turn the call back over to chat.
Speaker 4: cast position to fuel growth and execute on our long-term goals. We remain committed to driving additional operating leverage and achieving positive EBITDA in 2025 and cast break given in 2026. I'll now turn the call back over to chat. Thanks, Tyco.
Speaker 4: As discussed during the call, we had a solid start to the year and we are focused on three main areas. First, execute on our MRD business to further solidify our leadership position. Second, in immune medicine, advance our partner programs with Genentech and our internal R&D efforts in auto-immunity.
Speaker 4: And third, manage capital allocation and drive operational efficiencies. With that, I'd like to turn it back over to the operator and open it up for questions. Thank you, Chad. Thank you all. At this time, we will conduct the question and answer session.
Speaker 2: As a reminder, to ask the question, you will need to press star 1-1 on your telephone and wait for your name to be announced.
Speaker 2: So, if you draw your question, please press star one one again. Please stand by while we compile the Q&A roster.
Speaker 2: Please press star one one again. Please stand by while we compile the Q&A roster. Okay. Okay.
Speaker 2: Our first question.
Speaker 2: comes from the line of Mark. Massaro with B.I. with B.T. I'm sorry, IG.
Speaker 2: Mark your line if not open.
Speaker 5: Hey, thank you Mark from BTIG. Congrats guys on the quarter, I guess. I didn't hear too much about the integration with Epic other than you expected completed by the end of this year. I would love to just kind of get a sense for operationally what needs to happen.
Speaker 5: Are you getting close? What are some of the challenges and opportunities of achieving that by year end?
Speaker 6: Sure, Nitin, you want to take that one? Yes. So I think the epic integration is really progressing nicely. You know, we define the user interface and epic to order a classic, how the results will look in classic.
Speaker 6: We've done a lot of testing, end-to-end testing, and it all is progressing very well. And we'll go wide with a couple of pilot sites to do a proper thorough end-to-end integration testing. And this will be sometime in Q3.
Speaker 6: And then we're simultaneously lining up accounts that we bring online with Epic in the second half of the year. And that's also progressing very nicely. And we're seeing a lot of interest from our install base in this integration. And I think the real gating factor I see is the IT resources.
Speaker 6: expecting a small impact in the second house of 2023, but really a big impact in 2024.
Speaker 5: Okay, great. So it's nice to see DLBCL pick up, you know, to 3% of orders. I think in the past you've talked about how DLBCL is an indication that includes MRD assessment based on CTDNA.
Speaker 5: You know, related to this, you know, I think we recently saw quest diagnostics acquire Haystack oncology, which I thought was interesting. I would love to hear maybe your latest thoughts on what your view is on solid tumor MRD, if that's an area of interest.
Speaker 5: and where you might be in terms of thinking about tackling this internally or externally.
Speaker 4: Sure, maybe I'll make a few comments. Mark and then I'll hand it over to Nitin to discuss some of the technology. I mean, we're always looking for ways to expand our brand and either leverage our brand or leverage our channel.
Speaker 4: But we want to do that in a way that makes the most sense for us as a business. I should point out that there's a pretty significant total adjustable market opportunity in front of us just in the hematology space that we need to operate, execute on and commercialize. And that's our main area of focus right now.
Speaker 4: That being said, we do look at opportunities where, for example, we've got 70 reps in the field that have, I would say, kind of best in class, exceptional relationships with the HEMOC. And so that's one area that we look to leverage. And then secondly, to your question, we also have a brand in MRD particularly.
Speaker 4: space around MRT. I think it's incredibly validating and you've got some extremely large players out there that I think are increasingly interested in the MRT space. So I think that's great. And there are earlier stage. One of the main advantages of
Speaker 4: really the clone of seek franchise, there's, there's, it has several competitive modes around the business, including the fact that, you know, we've got, we're regulated by the FDA, many indications, we've got wide pair coverage, and we're deeply penetrated in clinical trials. So, you know, that being said, with respect to circulating tumor due DNA, maybe I'll pass it over to Nitten to give some comments on kind of what we're doing.
Speaker 6: before you know, you link the position to really spell in that area.
Speaker 6: And then, you know, we have a very strong, you know, infrastructure in terms of generating clinical data. We have relationships with all the KOLs. You know, we've got over 100 publications in this area. You know, even most recent, we saw a great published data in this area, but again, their sensitivity was 1 in a thousand. We are, you know, 1 in a...
Speaker 6: You know, they demonstrated data in setting pre-creepment, whereas our data is post-creepment when the tumor burden is much lower. So again, our speed data technology is very suited for lymphoid malignancies, and we are continuing to integrate in that area and we'll continue to use new products.
Speaker 2: Our next question comes from a line of David Westenberg with Piper.
Speaker 5: Sandra, David, give one moment for your live, isn't it? Hi, thank you for taking the question. Okay, so we're back to a really big number on the sequential order. So I kind of want to just maybe talk about the customer or the patient's thickness here. Maybe let's go back if we can. Can you talk about some of your older cohorts maybe, you know, because you've been around and that I had to mention
Speaker 5: with either CMS or some of the private payers. Just trying to think about how we can think about that waterfall theft in your business.
Speaker 6: For sure. Nitin, go ahead. Yeah, I mean, I think the only comment I'll make here is that, you know, our Medicare reimbursement is limited to the four tests, but we are working on reminder, and then hopefully we're able to start ceasefire
Speaker 6: you know, expanding that to add medical coverage for single tests beyond those four tests. So that's in the works.
Speaker 6: You know, as it relates to private pairs, you know, it's based on individual tests.
Speaker 6: So when a patient gets tested beyond forecast, we will recover with our private pairs. And then in terms of...
Speaker 6: you know, repeat testing, which I think the intent of your question, you know, we're currently averaging 1.6 tests per patient. You know, and this varies by indication. It's much higher in ALM. It's lower in other indications. And our, you know, expectation is that on average, this will go up to...
Speaker 5: Yeah. Got all right. And then I'll just ask one more short one. Can you talk about maybe some of the consolidation of the president's role? You know, maybe why wasn't that, you know, separated from the beginning? And then if we should expect any other kind of positions in the future that might be consolidated, I mean, I think you had no changes to kind of your op-ax and should be very sure that you have.
Speaker 4: and Burns, since last quarter, so I'm guessing not, but you know, just wanted to, you know, ask that and I'll hop back in queue after that. Thank you. Yeah, thanks for the question there, David. First, I want to just get out on the table. There are absolutely no performance issues or disagreements with Mark Adams. He actually did a really nice job.
Speaker 4: in building a top leadership team. And it's really that team is in place and I think will thrive under this new structure and under Julie's leadership. David, I think as you know, having covered this for a long time, Julie's been done almost every role, executive role within in the company and has intimate knowledge.
Speaker 4: and working knowledge of almost every function at Adaptive. And so the real reason that we did this is we wanted to align our operations and our R&D and commercial efforts across the company so that we could drive towards profitability and really executing on all our goals. So.
Speaker 4: Again, this is just the next iteration of the company, an evolution, where we thought there was an opportunity to consolidate these roles under one person.
Speaker 2: All right. Thank you so much for that. Everyone, I want to make a quick note. Please do not ask your question. And so you hear me say your line is open. We don't want to speak or submit anything.
Speaker 2: Got it. Thank you. All right. Thank you so much for that. Everyone, I want to make a quick note. Please do not ask your question until you hear me say your line is open. We don't want the speakers to miss anything.
Speaker 2: Our next question comes from the line of Derrick, De Bruins with Bank of America.
Speaker 2: Our next question comes from the line of Derry D. Bruin with Bank of America. In one moment Derry, your line is now open.
Speaker 5: Great. Thank you. Hey, good afternoon. Hey, you had some really solid growth in your pharmaceutical services business. I'm just curious. We've heard some other companies talk about maybe a little bit of slowing, repartization of pipelines in the pharmaceutical pharmaceutical space. Can you sort of talk about what you're seeing?
Speaker 5: there, any sort of slow down or changes in terms of how some of your customers are growing or thinking about it. It's basically just sort of like a temperature check on what you're sort of seeing in the groups that our farmer service is based.
Speaker 4: Yeah, yeah, Derek, I'll make some comments and maybe Tyco wants to share and want to pile on here. But I think there's, first of all, there's nothing material that's a report in terms of a slowdown from our cost of customers. You know, that being said, I think there's two areas.
Speaker 4: that we're closely watching. One is the IRA, the Emplacement Reduction Act, and the second is just in terms of how the macroeconomic headwinds with kind of, you know, lesser degrees of funding for kind of small and midsize, kind of biotech companies that we've potentially used our services, cells.
Speaker 4: It's something we're keeping an eye on, but we don't see, and it's also reflected, frankly, in our guidance range. And so there's nothing to report above and beyond that, at least in terms of impact on our business. You have relatively small emerging biopharm exposure.
Speaker 4: would be my guess. We do. We have some. Our BioFarmor exposure really is kind of a cross-supboard from small and mid-size to almost all large pharma and biotech can use us in some capacity, whether in MRD trials or for pharma services from our immune medicine business.
Speaker 5: So, as we're sort of like, we're sort of out and finished with the pandemic and obviously, you know, comps are a little bit weird because of the Oma Crom last year. How should we think about order pacing now that we're sort of back to more...
Speaker 5: seasonal traditional sort of things. Can you just sort of help us sort of look at how we should think about order and test volume in the cleft of the business as we go for the next couple of quarters?
Speaker 4: Sure. And then you want to comment on the closing test by the next three quarters.
Speaker 6: Yes, I mean, I think look, you know, all the leading indicators look very favorable. New HCPs and accounts grew greater than 50%. Unique patients tested grew greater than 70%. All the indications, all four indications that we play in grew a double digit quarter or quarter.
Speaker 6: Sales force productivity has increased by 77% from a prior year. Our community business grew by 45% quarter-were quarter, blood testing grew by 30% quarter-were quarter. And then, you know, with expansion into DLBCL. And, you know, we're expanding into another non-harshens informa indication called mantle cell lymphoma.
Speaker 6: you know, 50% and, you know, onwards beyond that as well. So, you know, from my standpoint, I'm very optimistic about the Conocic Diagnostic Business. And likewise, I feel fairly strongly about our farmer business. We have a very strong pipeline of new deals that we're working through. So I expect that to be, you know, above 20% for the remainder of the year as well. Got it. And just to help you tell us. It's a great, yeah. Thank you.
Speaker 5: Hey, there it gets cycle. I just want to remind you, you know, we hit guided for the year to be kind of back half way If you think about Plano's seat, you know, just think about the epic integration we talked about earlier and the DLB seal ramp right just kind of you know getting off and obviously we doubled the sales force a year ago We're kind of anniversary in that now, but just think about you know momentum building in the back half of the year
Speaker 5: Can you give us some sense on the, I don't know, either the test volume, the revenue volume split between the different indications, ALL, multiple of myeloma, CLL and NHL? Now that you've got just sort of curious in terms of where we are and where you think you are penetrated in those markets. And just would like to get a sense of the flavor on just for what the revenue mixes from the different indications.
Speaker 6: You're knitting you want to take that? Yes, so I think we're primarily driven by my low-mind ELL.
Speaker 6: That sort of is a two major indication and I would say we are sort of close to 20% penetrated in the ALL market. We're probably 7 to 8% penetrated in the multiple myeloma market and then you know sub 5% in CLL and DL, BCL.
Speaker 6: And so longer range, you know, sort of in that, you know, by 2027 or so, I expect an overall market penetration to be above 20% across all the indications. And you know, a lot of growth will come from continued penetration multiple myeloma FND and BC over the world.
Speaker 2: Thank you very much. Thank you so much, Derek. Our next question.
Speaker 2: One moment comes from the line of Teyau Savant with Morgan's family. One moment. Your line is not over.
Speaker 2: of Teos, so va with Morgan's family. Your line is now over.
Speaker 7: Thank you for taking our questions. Regarding following up on the previous question here on regarding epic integration, what's pilot sites underway, how much of a driver is epic integration for a community uptake of empathy?
Speaker 7: taking our questions. Regarding following up on the previous question here on regarding epic integration, with Pilot Scythe underway, how much of a driver is epic integration for a community uptake of Clonopheek? Then. Thank you.
Speaker 6: Yes, so I think EPICS is primarily in our academic setting. That's where we see most of our EPIC installation going forward. We are looking at other EMRs that are dominant in the community setting. That's what we learn.
Speaker 6: get operational excellence going with Epic, we look at other EMRs as well. But in the interim, our penetration in the community is so small that just our expansion of our sales team with a focus on the community, that's what's driving the growth in community. And as I've stated before, we are very solid performance from our community business.
Speaker 6: A year ago, 8% of our tests came from the community. I, in Q1, this was 18% of our tests. And I expect for the full year, 20% of our business to come from community. And again, in the next four, three, four years, I expect 50% of our order volume.
Speaker 8: Wouldn't public.
Speaker 5: Okay, great. Thank you. All right. Thank you so much. Our next question comes from a line of Tom Stevens with Colin and company. That's on the quarter. Just a couple on on the gross margin and the consolidation. So I guess how long do you expect that consolidation to take? How much does it cost in dollar times and how much do you expect it to save in 2024? And I've got to follow up with that. Yeah, we we haven't. So I mean a couple of things to think about. The big impact on gross margin this quarter was, you know, Genentech amortization and MRD milestones, right? Those are very high margin, you know, 100% in case of the MRD milestones. So
Speaker 5: It will talk a lot about course margins, but it is a big focus internally.
Speaker 4: Actually, Tom, every quarter we're getting more tests in my Loma, we've kind of done in blood, and we continue to kind of sell the merits of blood-based testing. So, obviously, the continued data readouts will help with clinical utility and comparability studies, but the reality is that part of our growth trajectory is based on kind of the increase in blood-based testing across multiple indications, including multiple Loma. Got it, and then just one last one, more on the weed.
Speaker 5: Your milestone pipeline for MRD looks about 50 million bigger. I guess, does that change any of your pacing expectations? And kind of...
Speaker 5: Where do you expect the pacing of that 400 million to kind of be in the out here, especially with the key to deal? Sorry. Yeah, so you did hear that when you were a guy, for this year, mid-single digit, millions and milestones, rather than not commenting on 2024 at this point. But what we talked about is that we've got line of sight to around half a...
Speaker 9: half those 400 million and 74 active trials. Next year will be a bigger year for milestones for sure, just kind of given what we know about trial readouts. And when we officially guide, you'll hear more about it then. Keep in mind, all the milestones at this point are also on secondary endpoints. So should the FDA move forward and endorse MRD as a primary end point, that would be upside relative to what we previously talked about.
Speaker 5: Great. That's what we have tonight. Thank you guys. Thank you so much. All right. Thank you so much. Our next question comes from a line of Andrew Brackman with William Blair. Your line is now open. Hey everyone. This is Dustin on the line for Andrew. This is just a more broader strategic question. You know, it's been some time since you've reorganized the business into the immune medicine and MRD segments.
Speaker 4: just wondering how that reorganization has helped you guys in terms of commercialization and capital allocation. Yeah, it's a really good question. It's helped quite a bit, particularly in the area of focus. Right, we now have two focused.
dedicated teams with very clear objectives as to what they need to deliver, kind of not only this year, but in terms of the long-range strategic plan of the company. So we've, you know, if you look at kind of our MRD objectives, which are clearly laid out, we know exactly what we need to do. And then similarly in the immune medicine business.
both in our partner program and then in our deep programs for drug discovery, we have very clearly defined kind of milestones and kind of go-no-go decisions. So from, you know, a perspective of capital allocations, we can be very clear as to what we're investing in and what the growth trajectory looks like in each one of those businesses.
Great, thanks for that. And then one more maybe on your long-term guidance you guys laid out earlier this year. And in terms of the range, you know, the 20 to 30 percent, just wondering what could bring me to the high end of that range? What could be sources of upside there? And then looking at below and the range of 20 percent. And then looking at below and the range of 20 percent.
We'll keep bringing you guys down there. And then additionally, once the first quarter, we can expect some sort of adjusted EBITDA profitability if you have any visibility there. Thank you. Thank you.
Sure. I mean, some of the swing factors in the outlook are around MRD, obviously clinical volume growth to the extent there's upside there. That could be a factor. We talked about MRD milestones earlier and how we've been fairly thoughtful about kind of risk adjusting those. We put a 30 to 50% probability of success on those milestones. To the extent there's better odds there, that would be upside.
I mean, medicine obviously, additional form of deals would be if the potential driver beyond what we've modeled and anything with Genentech that is upside relative to either timing or incremental program set that we haven't announced or assigned. So those would be the main things. Anything Chad or Sharon, you would do it at? I think that captures the well-tech up. Yeah, and it's all organic. I received we did something and if you talked about solitude or earlier, I mean, if we move down to another path that would be.
Our next question will be coming from the line of Salveen witchster with Goldman Sachs. Your line is now open.
Hey guys, good evening and thanks for taking the question. This is Elizabeth on for Salveen. I wanted to ask on the drug discovery effort. So it sounds like this year is really a year for building the infrastructure and building up the engine to drive the drug discovery vertical. So I wanted to know what you hope to learn this year.
as you optimize for the personalized product and any kind of concrete timelines you can share there on potential INDs and then what you're also hoping to learn on the Autoimmune Drug Discovery front. Thank you.
Yeah, thanks Elizabeth. So as Chad mentioned, in terms of the IND, there's the 1IND acceptance for the first self-serif program that is included in our 223 guidance, no additional timing on additional IND.
are ones that we can wear in a position to certainly highlight or discuss, but certainly we'll provide updates as appropriate. Related to the fully personalized approach, absolutely we are scaling, our regulated infrastructure in South-Sarim, SISCOF with our dedicated lab for the fully-to-
As we've indicated, it's focused to leverage our existing capabilities in auto-immunity. Specifically, we've highlighted multiple processes in area focus as well as IBD. And there we are very focused in terms of a proof point to get to at least one novel target in auto-immunity that...
where we generate sufficient data to warrant additional investments with the goal of expanding the pipeline and entering into the clinic. Got it. And when do you think we'll have some more clarity on that internal pipeline and kind of concrete guidance around milestones for that program?
Yeah, right now, as we said, we're head down in terms of R&D to get to that novel target. We're certainly excited by the progress we're making. So we're not in the position right now to elaborate, but certainly as we get more information, the goal really is to validate that target and then assess based on compelling data.
whether it warrants further investments and will certainly update as these progress throughout the year.
Dan Limer with
A woman with credit, sweet, and one woman.
Credit Suisse. One moment. Your line is now.
Great, thank you. So I have a question on gross margin. The 50% gross margin figure in the quarter, is that the right baseline now to think about the business absent milestone payments? I mean, look, as I said before, the two big drags were Genentech and the lack of MRD milestones, right? So in any given quarter, we have more MRD milestones, which are 100% gross margin.
And we have talked about kind of margins at scale being in the 70 plus percent range, but that you know, it's we have as Tyco mentioned a very kind of rigorous internal program to look at how we are kind of focused on our margins. And that is again, it's also one of the reasons.
is something that fuel is driving in coordination with Tiger. I appreciate that. Thank you. And then as my follow up, can you speak to how the pharmaceutical services business is performing within immune medicine and what is the outlook? I think Nitten commented on 20% plus growth for pharmaceutical services, but I think that was just specific for MRG.
Yeah, happy to elaborate. So as we've mentioned, last year in 2022, our pharma services business in immune medicine substantially grew by 67% versus 2021. And so we aim to continue this trajectory with double digit percent growth.
The 20 to 30% CAGR over the next three to five years does apply to our pharma and immune medicine business in terms of our forecast. And the growth this year, as you saw the contribution in Q1 2023, was of 7 million or so, almost half of the 16 million for immune medicine. So we're excited by.
the various growth levers and sources of revenue that we're generating for our immune medicine business and aim to grow that through this year and the years beyond. Okay thank you. All right. Thank you so much for that. All right.
At this time, there are no more questions, and this call will now be concluded. Thank you for your participation in today's conference. This does conclude the program, and you may now disconnect.
for General
qu.
I.
Be.